item management s discussion and analysis of financial condition and results of operations the following discussion and analysis should be read in conjunction with selected consolidated financial data and the company s consolidated financial statements and notes thereto included elsewhere in this report 
in addition to the historical information contained herein  the discussions in this report may contain forward looking statements that involve risks and uncertainties 
the company s actual results could differ materially from those discussed herein 
overview the company provides a broad range of value added services and products focused on chemical analysis to the worldwide pharmaceutical  medical device and biotechnology industries 
the company s customer focused approach and its high quality services and products enable it to serve as a value added partner in solving complex scientific problems by providing cost effective results to its customers on an accelerated basis 
founded in in lansing  michigan and relocated to west lafayette  indiana in  the company has experienced growth primarily through internal expansion  supplemented by strategic acquisitions 
as part of its internal growth strategy  the company has developed technical specialties in such areas as chromatography  electrochemistry  in vivo sampling and mass spectrometry 
the company s growth has strategically positioned it to take advantage of globalization in the marketplace and to provide new services and areas of technical expertise to its customers 
throughout its history  the company has taken steps to position itself as a global leader in the analytical chemistry field 
development of the company s infrastructure began in when it established relationships with several customers and multiple international distributors 
in  the company increased its sphere of influence to include japan with the creation of bas japan  an independent distributor 
in  the company enhanced its computer software expertise by acquiring interactive microware  inc in state college  pennsylvania 
in  the company began offering contract services to customers that lacked the time or expertise to perform certain analyses using the company s analytical products 
in  the company acquired a distributor  bas instruments ltd  to further solidify its presence in the united kingdom 
in  the company acquired a manufacturer of veterinary monitoring and diagnostic equipment  bas vetronics  to provide additional preclinical support 
in  the company acquired a contract services firm  bas analytics ltd  to offer local service in the united kingdom 
in  the company also acquired a contract services firm  bas evansville  to offer preclinical services 
revenues are derived principally from i analytical services provided to customers and ii the sale of the company s analytical instruments and other products 
both methods of generating revenue utilize the company s ability to identify  isolate and resolve client problems relating to the separation and quantification of individual substances in complex mixtures 
the company supports the pharmaceutical industry by focusing on analytical chemistry for biomedical research  diagnostics  electrochemistry and separations science 
the company s analytical products are sold primarily to pharmaceutical firms and research organizations 
principal customers include scientists engaged in drug metabolism studies  as well as those engaged in basic neuroscience research 
the company was the first to commercialize the liquid chromatography and electrochemistry technology which is now the worldwide standard for the determination of neurotransmitter substances 
research products include in vivo sampling devices  reagent chemicals  electrochemical apparatus and sensors 
the company s pharmaceutical service contracts generally have terms ranging from several weeks to several years 
a portion of the contract fee is generally payable upon acceptance of the agreement with the balance payable in installments over the life of the contract 
the contracts are broken down into discrete units of deliverable services for which a fixed fee for each unit is established 
revenue and related direct costs are recognized as specific contract terms are fulfilled under the percentage of completion method utilizing units of delivery 
the termination of a contract results in no material adjustments to revenue or direct costs previously recognized 
the company is entitled to payment for all work performed through the date of notice of termination and all costs associated with termination of a contract 
revenue from the sale of the company s products and the related costs are recognized upon shipment of the products to customers 
the company s management believes that fluctuations in the company s quarterly results are caused by a number of factors  including the company s success in attracting new business  the size and duration of service contracts  the timing of its clients decisions to enter into new contracts  the cancellation or delays of on going contracts  the timing of acquisitions and other factors  many of which are beyond the company s control 
in fiscal  of the company s total revenue was derived from customers located outside the united states 
these markets tend to be much more volatile than the united states market 
significant governmental  regulatory  political  economic and cultural issues or changes could adversely affect the growth or profitability of the company s business activities in any such market 
results of operations the following table sets forth  for the periods indicated  certain statement of operations data as a percentage of total revenue 
percentage of revenue year ended september  service revenue product revenue total revenue cost of service revenue cost of product revenue total cost of revenue gross profit operating expenses selling research and development general and administrative total operating expenses operating income loss other income expense  net income loss before income taxes income taxes benefit net income loss year ended september  compared with year ended september  total revenue for the year ended september  decreased to million from million for the year ended september  service revenue increased to million for the year ended september  from million for the year ended september   primarily as a result of the addition of preclinical services through the acquisition of tps  inc this increase was more than offset with the decrease in products 
product revenue decreased to million for the year ended september  from million for the year ended september  primarily due to the decrease in the sales to the pacific rim and europe 
costs of revenue increased to million for the year ended september  from million for the year ended september  this increase of million was largely due to costs of services from the acquisition of toxicology pathology systems 
costs of revenue for the company s services increased to as a percentage of services revenue for the year ended september  from of services revenue for the year ended september  due to the addition of costs of services from the acquisition of tps  inc costs of revenue for the company s products decreased to as a percentage of product revenue for the year ended september  from of product revenue for the year ended september   due primarily to a change in product mix 
selling expenses for the year ended september  decreased to million from million during the year ended september  due to decreased foreign commission expense 
research and development expenses for the year ended september  decreased to million from million for the year ended september  due to the decrease in research grant activity 
general and administrative expenses for the year ended september  increased to million from million for the year ended september   primarily as a result of the addition of expenses from the acquisition of tps  inc other income expense  net  was  in the year ended september  as compared to  in the year ended september  as a result of the increase in interest expense due to increased use of the line of credit 
the company s effective tax rate for was compared to for fiscal this decrease was primarily due to nondeductible foreign losses incurred in fiscal year ended september  compared with year ended september  total revenue for the year ended september  increased to million from million for the year ended september  the net increase of million related primarily to increased revenue from services  which increased to million for the year ended september  from million for the year ended september  as a result of the expansion of types and volume of services provided by the company 
during this same period  product revenue decreased to million for the year ended september  from million for the year ended september  primarily as a result of decreased sales in the asian electrochemistry markets 
costs of revenue increased to million for the year ended september  from million for the year ended september  this increase of million was largely due to the addition of a uk services facility 
costs of revenue for the company s services increased to as a percentage of services revenue for the year ended september  from of services revenue for the year ended september  due to an increase in services support staff 
costs of revenue for the company s products increased to as a percentage of product revenue for the year ended september  from of product revenue for the year ended september   due primarily to a change in product mix 
selling expenses for the year ended september  decreased to million from million for the year ended september  due to decreased foreign commission expense 
research and development expenses for the year ended september  decreased to million from million for the year ended september  due to the decrease in research grant activity 
general and administrative expenses for the year ended september  increased to million from million for the year ended september   primarily as a result of an increase in administrative staff expense and an increase in health care costs 
other income expense  net  was  in the year ended september  compared to  in the year ended september  as a result of the increase in interest expense due to an increase in long term debt 
the company s effective tax rate for was compared to for fiscal this decrease was primarily due to a decrease in nondeductible foreign losses incurred in fiscal liquidity and capital resources since its inception  the company s principal sources of cash have been cash flow generated from operations and funds received from bank borrowings and other financings 
at september   the company had cash and cash equivalents of  compared to cash and cash equivalents of million at september  the decrease in cash resulted primarily from capital expenditures made to expand the company s facilities and operations  including the acquisition of tps  inc the company s net cash used by operating activities was  for the year ended september  cash used by operations during the year ended september  consisted of net loss of  less non cash charges of  plus a net increase of  in operating assets and liabilities 
the most significant decrease in operating liabilities related to accounts payable  which decreased  at september  cash used by investing activities decreased to million for the year ended september  from million for the year ended september   primarily as a result of the reduction of company purchases of laboratory equipment 
cash provided by financing activities for the year ended september  was million due to the increased use of the line of credit offset by payments on long term debt 
the company s net cash provided by operating activities was million for the year ended september  cash provided by operations during the year ended september  consisted of net income of  plus non cash charges of  less a net increase of  in operating assets and liabilities 
the most significant increase in operating assets related to trade accounts receivable  which increased  at september  cash used by investing activities decreased to million for the year ended september  from million for the year ended september   primarily as a result of the company s completion of construction of additional facilities 
cash provided by financing activities for the year ended september  was million due to the increase in debt 
total expenditures by the company for property and equipment were million  million and million in fiscal  and  respectively 
expenditures made in connection with the expansion of the company s operating facilities and purchases of laboratory equipment account for the largest portions of these expenditures 
the capital investments relate to the purchase of additional laboratory equipment corresponding to anticipated increases in research services to be provided by the company 
the company expects to make other investments to expand its operations through internal growth and strategic acquisitions  alliances and joint ventures 
however  the company currently has no firm commitments for capital expenditures 
based on its current business activities  the company believes that cash generated from its operations  amounts available under its existing bank line of credit and credit facility will be sufficient to fund the company s working capital and capital expenditure requirements for the foreseeable future 
the company has a working capital line of credit  which expires april  and allows borrowings of up to  interest accrues monthly on the outstanding balance at the bank s prime rate minus basis points at september  or at the london interbank offered rate libor plus as elected by the company 
the line is collateralized by inventories and accounts receivable and requires the company to maintain certain financial ratios 
the balance outstanding on this line of credit at september  was million 
on june  the company obtained a  commercial mortgage with a bank 
the mortgage note requires monthly principal payments of  plus interest followed by a final payment for the unpaid principal amount of  due june  interest is charged at the one month libor rate plus basis points at september  
inflation the company believes that inflation has not had a material adverse effect on its business operations or financial condition 
new accounting pronouncements please refer to the notes to consolidated financial statements for a discussion of recently issued accounting standards 
item a 
quantitative and qualitative disclosures about market risk not applicable 

